Skip to main content
. 2021 Sep 21;14(10):100587. doi: 10.1016/j.waojou.2021.100587

Table 1.

Baseline characteristics of respondents.

Baseline Characteristics (n = 41)
Female sex – n (%) 34 (90)
Age – mean, years (range) 43 (20–79)
Duration of omalizumab therapy – n (%)
  • -

    < 1 year

 11 (27)
  • -

    1–4 years

 25 (61)
  • -

    5–9 years

 5 (12)
Omalizumab dosing intervals – n (%)
  • -

    3-weekly

 7 (17)
  • -

    4-weekly

 24 (59)
  • -

    5-weekly

 5 (12)
  • -

    6-weekly

 5 (12)
Omalizumab dose – n (%)
  • -

    300 mg

 34 (83)
  • -

    450 mg

 6 (15)
  • -

    600 mg

 1 (2)
Baseline satisfaction with omalizumab in management of symptoms – n (%)
  • -

    Extremely Satisfied

 27 (66)
  • -

    Satisfied

 10 (24)
  • -

    Somewhat Satisfied

 3 (7)
  • -

    Dissatisfied

 1 (2)
  • -

    Extremely Dissatisfied

 0 (0)